Papers/PMID:33372679
Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial.
The international journal of neuropsychopharmacology2020The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
resveratrol — no detected effect on hamilton Depression Rating Scale (HDRS) total score
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“HDRS scores and its changes, ESRS score, and frequency of other complications were not significantly different between resveratrol and placebo groups.”
Quoted verbatim from Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- 200 mg/d
- Population
- Patients with stable schizophrenia on a stable dose of risperidone in both arms; resveratrol versus matched placebo
Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial.2020PMID:33372679Permalink